REFERENCES
1. Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin 2021;71:381-406.
2. Abdelfattah N, Kumar P, Wang C, et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun 2022;13:767.
3. Puchalski RB, Shah N, Miller J, et al. An anatomic transcriptional atlas of human glioblastoma. Science 2018;360:660-3.
4. Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. Nat Genet 2016;48:768-76.
5. Kim J, Lee IH, Cho HJ, et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 2015;28:318-28.
6. Abou-El-Ardat K, Seifert M, Becker K, et al. Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. Neuro Oncol 2017;19:546-57.
7. Wu L, Wu W, Zhang J, et al. Natural coevolution of tumor and immunoenvironment in glioblastoma. Cancer Discov 2022;12:2820-37.
8. Seferbekova Z, Lomakin A, Yates LR, Gerstung M. Spatial biology of cancer evolution. Nat Rev Genet 2023;24:295-313.
9. Ozawa T, Riester M, Cheng YK, et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell 2014;26:288-300.
10. Sakthikumar S, Roy A, Haseeb L, et al. Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes. Genome Biol 2020;21:127.
11. Wang Q, Hu B, Hu X, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 2017;32:42-56.e6.
12. Alzial G, Renoult O, Paris F, Gratas C, Clavreul A, Pecqueur C. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene 2022;41:613-21.
13. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344:1396-401.
14. Marques C, Unterkircher T, Kroon P, et al. NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1. Elife 2021;10:e64846.
16. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
17. Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 2019;178:835-849.e21.
18. Castellan M, Guarnieri A, Fujimura A, et al. Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma. Nat Cancer 2021;2:174-88.
19. Johnson KC, Anderson KJ, Courtois ET, et al. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nat Genet 2021;53:1456-68.
20. Park MD, Silvin A, Ginhoux F, Merad M. Macrophages in health and disease. Cell 2022;185:4259-79.
21. Pombo Antunes AR, Scheyltjens I, Lodi F, et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci 2021;24:595-610.
22. Müller S, Kohanbash G, Liu SJ, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol 2017;18:234.
23. Hara T, Chanoch-Myers R, Mathewson ND, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 2021;39:779-792.e11.
24. Lin Z, Wen M, Yu E, et al. ANXA1 as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis and experimental validation. Front Cell Dev Biol 2021;9:659080.
25. Chen R, Chen C, Han N, et al. Annexin-1 is an oncogene in glioblastoma and causes tumour immune escape through the indirect upregulation of interleukin-8. J Cell Mol Med 2022;26:4343-56.
26. Araújo TG, Mota STS, Ferreira HSV, Ribeiro MA, Goulart LR, Vecchi L. Annexin A1 as a regulator of immune response in cancer. Cells 2021;10:2245.
27. Leslie J, Millar BJ, Del Carpio Pons A, et al. FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis. JCI Insight 2020;5:125937.
28. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008;216:15-24.
29. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 2020;5:28.
30. Meyer-Schaller N, Cardner M, Diepenbruck M, et al. A hierarchical regulatory landscape during the multiple stages of EMT. Dev Cell 2019;48:539-553.e6.
31. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61.
32. Hu B, Wang Q, Wang YA, et al. Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell 2016;167:1281-1295.e18.
33. Mei X, Chen YS, Chen FR, Xi SY, Chen ZP. Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging. Neuro Oncol 2017;19:1109-18.
34. Ding L, Li B, Zhao Y, et al. Serum CCL2 and CCL3 as potential biomarkers for the diagnosis of oral squamous cell carcinoma. Tumour Biol 2014;35:10539-46.
35. Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther 2021;6:127.
36. Yang M, McKay D, Pollard JW, Lewis CE. Diverse functions of macrophages in different tumor microenvironments. Cancer Res 2018;78:5492-503.
38. Huang Y, Hoffman C, Rajappa P, et al. Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res 2014;74:1011-21.
39. Chédeville AL, Lourdusamy A, Monteiro AR, Hill R, Madureira PA. Investigating glioblastoma response to hypoxia. Biomedicines 2020;8:310.
40. Ma K, Chen S, Chen X, Yang C, Yang J. S100A10 is a new prognostic biomarker related to the malignant molecular features and immunosuppression process of adult gliomas. World Neurosurg 2022;165:e650-63.
41. Tantyo NA, Karyadi AS, Rasman SZ, et al. The prognostic value of S100A10 expression in cancer. Oncol Lett 2019;17:1417-24.
42. Wan X, Guan S, Hou Y, et al. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts. Theranostics 2021;11:4975-91.
43. Chen P, Zhao D, Li J, et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-Null glioma. Cancer Cell 2019;35:868-884.e6.
45. Martin S, Cosset EC, Terrand J, Maglott A, Takeda K, Dontenwill M. Caveolin-1 regulates glioblastoma aggressiveness through the control of α5β1 integrin expression and modulates glioblastoma responsiveness to SJ749, an α5β1 integrin antagonist. Biochim Biophys Acta 2009;1793:354-67.
46. Nowicki MO, Hayes JL, Chiocca EA, Lawler SE. Proteomic analysis implicates vimentin in glioblastoma cell migration. Cancers 2019;11:466.
47. Mooney KL, Choy W, Sidhu S, et al. The role of CD44 in glioblastoma multiforme. J Clin Neurosci 2016;34:1-5.
48. Wang Y, Gu W, Wen W, Zhang X. SERPINH1 is a potential prognostic biomarker and correlated with immune infiltration: a pan-cancer analysis. Front Genet 2021;12:756094.
49. Sattiraju A, Kang S, Chen Z, et al. Spatial patterning and immunosuppression of glioblastoma immune contexture in hypoxic niches. bioRxiv 2022;3:482530.
50. Hu WM, Yang YZ, Zhang TZ, Qin CF, Li XN. LGALS3 is a poor prognostic factor in diffusely infiltrating gliomas and is closely correlated with CD163+ tumor-associated macrophages. Front Med 2020;7:182.
51. Wang S, Wu J, Zhao W, Li M, Li S. CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma. FASEB J 2023;37:e22848.
52. Gao Y, Liu B, Feng L, et al. Targeting JUN, CEBPB, and HDAC3: a novel strategy to overcome drug resistance in hypoxic glioblastoma. Front Oncol 2019;9:33.
53. Angelastro JM, Canoll PD, Kuo J, et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene 2006;25:907-16.
54. Chen Q, Han B, Meng X, et al. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma. Int J Cancer 2019;145:517-30.
